Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma.

Head & neck - 1 Aug 2018

Condello Vincenzo, Macerola Elisabetta, Ugolini Clara, De Napoli Luigi, Romei Cristina, Materazzi Gabriele, Elisei Rossella, Basolo Fulvio

Abstract excerpt

BACKGROUND: Circulating cell-free tumor DNA (ctDNA) in plasma is a promising noninvasive instrument for cancer monitoring. Detection of BRAFV600E on ctDNA of patients with papillary thyroid carcinoma (PTC) may represent an indicator of tumor aggressiveness and progression. METHODS: Eighty-three plasma samples were collected from 70 patients with thyroid nodules undergoing surgery and from 13 patients with PTC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Circulating Tumor DNA
Share to Gene Frequency

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasm Metastasis

Share to Polymerase Chain Reaction

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Source

Identifiers

PMID: 29566452
DOI: 10.1002/hed.25155

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma.PMID 29566452Read ↗

Circulating BRAFV600E in the diagnosis and follow-up of differentiated papillary thyroid carcinoma.Semantic proximity Read ↗

Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma.Semantic proximity Read ↗

Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.Semantic proximity Read ↗

Circulating Tumor DNA Harboring the BRAFV600E Mutation May Predict Poor Outcomes of Primary Papillary Thyroid Cancer Patients.Semantic proximity Read ↗

Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status.Semantic proximity Read ↗

Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas.Semantic proximity Read ↗

IS MEASUREMENT OF CIRCULATING TUMOR DNA OF DIAGNOSTIC USE IN PATIENTS WITH THYROID NODULES?Semantic proximity Read ↗

Study of peripheral BRAF(V600E) mutation as a possible novel marker for papillary thyroid carcinomas.Semantic proximity Read ↗

Potential of Liquid Biopsy in Papillary Thyroid Carcinoma in Context of miRNA, BRAF and p53 Mutation.Semantic proximity Read ↗

Detection of driver mutations in plasma cell-free nucleic acids in differentiated thyroid neoplasm.Semantic proximity Read ↗

Circulating BRAFV600E Levels Correlate with Treatment in Patients with Thyroid Carcinoma.Semantic proximity Read ↗

BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.